Labiana Health

Company snapshot

LABIANA Pharmaceuticals has an extensive experience in contract manufacturing services for the human pharmaceutical industry and provides services to many important multinational companies. Under the EU-GMP certificate, LABIANA Pharmaceuticals has a production plant with current authorisation for several pharmaceutical forms including tablet manufacturing and with a capacity of about 20 million un

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Labiana Health. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Labiana Health.

1. Jun 8, 2026 Clinical update

   HIPRA-HH-17 — Approved

2. Jun 8, 2026 Clinical update

   COVID-19 Vaccine HIPRA — Phase 2

View all clinical trial activity →

• What is Labiana Health?

  Hipra Human Health is a pharma organization headquartered in EU. Primary therapeutic focus areas include COVID-19. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pip

• Is Labiana Health publicly traded?

  Labiana Health appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Labiana Health develop or market?

  We link 6 drug profile(s) where Labiana Health is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/hipra-human-health-s-l#company-drugs.

• What are the latest developments for Labiana Health?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Labiana Health focus on?

  Labiana Health focuses on COVID-19 based on our analysis of their pipeline programs and drug development activities.